Session » Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy III: Innovative Therapeutic Strategies in Rheumatoid Arthritis
-
Abstract Number: 1842
High Rates of Failure after Biological DMARD Discontinuation While in Remission in a Japanese Multi-Center Registry
-
Abstract Number: 1843
Randomised Controlled Non-Inferiority Study of Dose Reduction and Withdrawal of Adalimumab and Etanercept in Rheumatoid Arthritis
-
Abstract Number: 1844
Identification of a Patient Phenotype Which Impacts Response to Therapy in Rheumatoid Arthritis Clinical Trials: Certolizumab Pegol Phase 4 Trial Data